

# C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/C0D4669EC344EN.html>

Date: November 2019

Pages: 136

Price: US\$ 3,500.00 (Single User License)

ID: C0D4669EC344EN

## Abstracts

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

### SUMMARY

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 28 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 5, 2, 1, 12 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Genetic Disorders, Hematological Disorders, Immunology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Male Health, Musculoskeletal Disorders, Ophthalmology, Respiratory and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Solid Tumor, Melanoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Neuroblastoma, Prostate Cancer, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Adenocarcinoma Of The Gastroesophageal Junction, Aplastic Anemia, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Critical Limb Ischemia, Epithelial Ovarian Cancer, Erectile Dysfunction, Fibrosis, Gastric Cancer, Glioblastoma Multiforme (GBM), Hematological Tumor, Hematopoietic Stem Cell Transplantation, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Kidney Fibrosis, Liver Cancer, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Myelodysplastic Syndrome, Myocardial Infarction, Neutropenia, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Immune Deficiency (PID), Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Stroke, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Thrombocytopenia, Triple-Negative Breast Cancer (TNBC), Unspecified, Vasomotor Symptoms (Non-Menopausal), Wet (Neovascular/Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

The latest report C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects

The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1

Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide

Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Overview

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Development

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Products

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Products under Development by Companies, H2 2019 (Contd..2), H2 2019  
Products under Development by Companies, H2 2019 (Contd..3), H2 2019  
Products under Development by Companies, H2 2019 (Contd..4), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by AdAlta Ltd, H2 2019  
Pipeline by Ambrx Inc, H2 2019  
Pipeline by Biokine Therapeutics Ltd, H2 2019  
Pipeline by BioLineRx Ltd, H2 2019  
Pipeline by Bristol-Myers Squibb Co, H2 2019  
Pipeline by Eli Lilly and Co, H2 2019  
Pipeline by FairJourney Biologics SA, H2 2019  
Pipeline by GlycoMimetics Inc, H2 2019  
Pipeline by Harmonic Pharma, H2 2019  
Pipeline by Kymab Ltd, H2 2019  
Pipeline by Pfizer Inc, H2 2019  
Pipeline by Polyphor AG, H2 2019  
Pipeline by Que Oncology Inc, H2 2019  
Pipeline by Tactiva Therapeutics LLC, H2 2019  
Pipeline by TaiGen Biotechnology Co Ltd, H2 2019  
Pipeline by Upsher-Smith Laboratories Inc, H2 2019  
Pipeline by X4 Pharmaceuticals Inc, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019  
Dormant Products, H2 2019 (Contd..3), H2 2019  
Dormant Products, H2 2019 (Contd..4), H2 2019  
Dormant Products, H2 2019 (Contd..5), H2 2019  
Discontinued Products, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Top 10 Indications, H2 2019  
Number of Products by Mechanism of Actions, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Routes of Administration, H2 2019  
Number of Products by Stage and Routes of Administration, H2 2019  
Number of Products by Molecule Types, H2 2019  
Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

AdAlta Ltd  
Ambrx Inc  
Biokine Therapeutics Ltd  
BioLineRx Ltd  
Bristol-Myers Squibb Co  
Eli Lilly and Co  
FairJourney Biologics SA  
GlycoMimetics Inc  
Harmonic Pharma  
Kymab Ltd  
Pfizer Inc  
Polyphor AG  
Que Oncology Inc  
Tactiva Therapeutics LLC  
TaiGen Biotechnology Co Ltd  
Upsher-Smith Laboratories Inc  
X4 Pharmaceuticals Inc

## I would like to order

Product name: C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C0D4669EC344EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C0D4669EC344EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970